Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ESMO 2025
AI and Machine Learning
Merck grows more ambitious about 'workhorse' TROP2 ADC
Merck has already registered 15 global phase 3 trials for its Kelun-partnered TROP2 antibody-drug conjugate, sac-TMT.
Angus Liuu
Oct 20, 2025 4:00pm
Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC
Oct 19, 2025 10:45am
Novartis' Pluvicto slows progression in earlier prostate cancer
Oct 19, 2025 10:30am
AZ faces FDA challenge as Imfinzi-Lynparza miss survival goal
Oct 19, 2025 4:15am
ESMO: Datroway data edge out Trodelvy in first TROP2 face-off
Oct 19, 2025 2:30am
Keytruda, Padcev cut risk of death by 50% in MIBC patient subset
Oct 18, 2025 10:30am
